| scholarly article | Q13442814 |
| P2093 | author name string | Toshiyuki Mori | |
| Masanori Sugiyama | |||
| Takashi Watanabe | |||
| Satsuki Matsushima | |||
| Junji Furuse | |||
| Yasuo Ohkura | |||
| Masaaki Yokoyama | |||
| Hiroaki Ohnishi | |||
| Kouki Ohtsuka | |||
| P2860 | cites work | Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies | Q37767871 |
| Chemotherapy for the biliary tract cancers: moving toward improved survival time | Q37983498 | ||
| Toward personalized treatment of advanced biliary tract cancers | Q38030656 | ||
| A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States | Q38467833 | ||
| KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients | Q39820471 | ||
| Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan | Q40196680 | ||
| A simple and sensitive method for detecting major mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene in non-small-cell lung carcinoma | Q40266820 | ||
| Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma | Q43005729 | ||
| FBXW7/hCDC4 is a general tumor suppressor in human cancer. | Q45345209 | ||
| Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers | Q46488823 | ||
| Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? | Q54361260 | ||
| Genetic alterations in gallbladder adenoma, dysplasia and carcinoma | Q74033242 | ||
| Histological and genetic changes in malignant transformation of gallbladder adenoma | Q78096954 | ||
| K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China | Q78358414 | ||
| Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan | Q83097384 | ||
| PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis | Q26992267 | ||
| PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies | Q27851465 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients | Q33179641 | ||
| Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas | Q33750719 | ||
| Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients | Q33809458 | ||
| Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma | Q33814916 | ||
| Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer | Q34094717 | ||
| Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. | Q34554584 | ||
| PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors | Q34769343 | ||
| Best Practice No 176: Updated recommendations for HER2 testing in the UK | Q35587451 | ||
| PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations | Q35808438 | ||
| Gallbladder cancer worldwide: geographical distribution and risk factors | Q36362499 | ||
| Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer | Q37274280 | ||
| Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer | Q37287501 | ||
| EGFR and HER2 expression in advanced biliary tract cancer | Q37362858 | ||
| Genetics of biliary tract cancers and emerging targeted therapies | Q37765099 | ||
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 33-39 | |
| P577 | publication date | 2016-12-13 | |
| P1433 | published in | Japanese clinical medicine | Q27724884 |
| P1476 | title | KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers | |
| P478 | volume | 7 |
Search more.